One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that…
Myeloma
Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according…
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and…
KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for…
A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma.
Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex…
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a…
A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including…
